A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Clinical trial NCT06119581 · RECRUITING
Trial details
- NCT number
- NCT06119581
- Sponsor
- Eli Lilly and Company
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-21
- Primary completion
- 2027-11-01
- Enrollment
- 1264
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.